Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 1/20 | 0.63 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.63 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | KYAT1 | Q16773 | 5/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | DGKA | P23743 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156735 | 1.00 | APOBEC3A (0.63) | APOBEC3AAPOBEC3GFAAHKYAT1CES1 | |
| SCHEMBL6156730 | 1.00 | APOBEC3A (0.63) | APOBEC3AAPOBEC3GFAAHKYAT1CES1 | |
| SCHEMBL7640240 | 0.94 | APOBEC3A (0.61) | APOBEC3AAPOBEC3GFAAHKYAT1CES1 | |
| SCHEMBL7643168 | 0.92 | APOBEC3A (0.59) | APOBEC3AAPOBEC3GFAAHCES1CES2 | |
| SCHEMBL7635778 | 0.92 | APOBEC3A (0.59) | APOBEC3AAPOBEC3GFAAHCES1CES2 | |
| SCHEMBL7639888 | 0.92 | APOBEC3A (0.59) | APOBEC3AAPOBEC3GFAAHCES1CES2 | |
| SCHEMBL7645072 | 0.88 | APOBEC3A (0.57) | APOBEC3AAPOBEC3GFAAHKYAT1CES1 | |
| SCHEMBL9331340 | 0.84 | FAAH (0.68) | APOBEC3AAPOBEC3GFAAHTP53MAPT | |
| SCHEMBL9331344 | 0.84 | FAAH (0.68) | APOBEC3AAPOBEC3GFAAHTP53MAPT | |
| SCHEMBL7635721 | 0.82 | APOBEC3A (0.56) | APOBEC3AAPOBEC3GFAAHKYAT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924300-B2 | Oxyiminoalkanoic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| EP-1077957-B1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-08-04 | — | — | EP | disclosed |
| EP-1428531-A1 | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| US-6495581-B1 | DRUG FOR TREATING DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE, ARTERIAL SCLEROSIS AND IMPROVING INSULIN RESISTANCE, INFLAMMATORY DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-6251926-B1 | OXYIMINOALKANOIC ACID DERIVATIVES HAVING HYPOGLYCEMIC EFFECT AND HYPOLIPIDEMIC EFFECT, IS USEFUL FOR TREATMENT OF DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE INFLAMMATORY DISEASE AND ARTERIOSCLEROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-1077957-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058510-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-18 | — | — | WO | disclosed |
| EP-0044115-B2 | THERMOSETTING COATING COMPOSITION CONTAINING A BLOCKED ACID CATALYST | AKZO N.V. (NL) | 1987-06-03 | — | — | EP | disclosed |
| EP-0044115-B1 | THERMOSETTING COATING COMPOSITION CONTAINING A BLOCKED ACID CATALYST | AKZO N.V. (NL) | 1984-10-10 | — | — | EP | disclosed |
| EP-0044115-A1 | Thermosetting coating composition containing a blocked acid catalyst | AKZO N.V. (NL) | 1982-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | GPR119, IRS1, CPT1A | APOBEC3A 4872/4885APOBEC3G 4881/4885FAAH 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.